Recent Company News

• 12:59 PM ET Apr 28, 2026
  

  Transcript Intelligence: Swedish Orphan Biovitrum Q1 Earnings Guidance

• 12:58 PM ET Apr 28, 2026
  

  Transcript Intelligence: Swedish Orphan Biovitrum Q1 Earnings Themes

• 12:58 PM ET Apr 28, 2026
  

  Transcript Intelligence: Swedish Orphan Biovitrum Q1 Earnings Q&A

• 02:40 AM ET Apr 28, 2026
  

  StreetAccount Metrics Recap - Swedish Orphan Biovitrum Q1 Earnings (SEK 398.60, 0.00)

• 02:14 AM ET Apr 28, 2026
  

  Swedish Orphan Biovitrum reports Q1 Adj. EPS SEK4.07 vs FactSet SEK3.63 [6 est, SEK3.21-4.04]; confirms FY guidance (SEK 398.60, 0.00)

• 08:02 AM ET Apr 27, 2026
  

  StreetAccount Consensus Metrics Preview - Swedish Orphan Biovitrum Q1 Earnings (SEK 398.20, -2.00)

• 04:23 PM ET Apr 09, 2026
  

  Swedish Orphan Biovitrum announces Health Canada approval for EMPAVELI for treatment of C3G and primary IC-MPGN (SEK 402.00, 0.00)

• 05:01 AM ET Mar 31, 2026
  

  Swedish Orphan Biovitrum publishes Sustainability Report for 2025 (SEK 380.00, -3.60)

• 02:06 AM ET Mar 30, 2026
  

  Swedish Orphan Biovitrum announces EMA validates indication extension application for Tryngolza for the treatment of sHTG (SEK 385.60, 0.00)

• 05:11 AM ET Mar 27, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning